Chronic myeloid leukemia and HIV-infection

References

• Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101: 317–324
   PubMed Web of Science ®Google Scholar
• Goedert J J, Cote T R, Virgo P, Scoppa S M, Kingma D W, Gail M H, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833–1839
   PubMed Web of Science ®Google Scholar
• Kravcik S, Hawley-Foss N, Victor G, Angel J B, Garber G E, Page S, et al. Causes of death of HIV-infected persons in Ottawa, Ontario, 1984–1995. Arch Intern Med 1997; 157: 2069–2073
   PubMed Web of Science ®Google Scholar
• Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med 1992; 93: 387–390
   PubMed Web of Science ®Google Scholar
• Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 14–19
   PubMed Web of Science ®Google Scholar
• Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin J M, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663–1671
   PubMed Web of Science ®Google Scholar
• Palella F J, Jr, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860
   PubMed Web of Science ®Google Scholar
• Barbone E, Girolami A, Randi M L. HIV infection and polycythemia vera: a relationship worth pursuing?. J Med 1993; 24: 409–410
   PubMedGoogle Scholar
• Drabick J J, Magill A J, Smith K J, Nutman T B, Benson P M. Hypereosinophilic syndrome associated with HIV infection. Military Medical Consortium for Applied Retroviral Research. South Med J 1994; 87: 525–529
   PubMed Web of Science ®Google Scholar
• May L P, Kelly J, Sanchez M. Hypereosinophilic syndrome with unusual cutaneous manifestations in two men with HIV infection. J Am Acad Dermatol 1990; 23: 202–204
   PubMed Web of Science ®Google Scholar
• Modest G A, Cooley T P, Zacks J F. HIV and refractory anemia with excess blasts (RAEB). Am J Hematol 2002; 70: 318–319
   PubMed Web of Science ®Google Scholar
• Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M, et al. Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med 2001; 40: 795–801
   PubMed Web of Science ®Google Scholar
• Sassaki M G, Souza C A, Siciliano R F, Leite A G, Padilha S L. Polycythemia vera in a patient with the human immunodeficiency virus: a case report. Braz J Infect Dis 2000; 4: 204–207
   PubMedGoogle Scholar
• Serena M, Guido C, Emanuela B, Enrico G, Simona S, Daniela C, et al. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. J Clin Oncol 2006; 24: e6–e7
   PubMedGoogle Scholar
• Taha H M, Kaplan B H. Polycythemia vera in a patient with acquired immunodeficiency syndrome. Am J Hematol 1998; 58: 248–249
   PubMed Web of Science ®Google Scholar
• van den Berg H, Scherpbier H J, Kroes W. Myelodysplastic syndrome in an HIV–1-infected infant. Med Pediatr Oncol 1999; 32: 385
   PubMedGoogle Scholar
• Tsimberidou A M, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, et al. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res 2004; 28: 657–660
   PubMed Web of Science ®Google Scholar
• Zucker-Franklin D, Termin C S, Cooper M C. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol 1989; 134: 1295–1303
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879–894
   PubMed Web of Science ®Google Scholar
• Antoniou T, Tseng A L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44: 111–145
   PubMed Web of Science ®Google Scholar
• Burman W, Orr L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. Aids 2000; 14: 2793–2794
   PubMed Web of Science ®Google Scholar
• Oostendorp R L, Beijnen J H, Schellens J H, Tellingen O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed Chromatogr 2007; 21: 747–754
   PubMed Web of Science ®Google Scholar
• Parise R A, Ramanathan R K, Hayes M J, Egorin M J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 39–44
   PubMed Web of Science ®Google Scholar
• Rochat B, Fayet A, Widmer N, Lahrichi S L, Pesse B, Decosterd L A, et al. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J Mass Spectrom 2008, Feb 20 [epub]
   PubMed Web of Science ®Google Scholar
• Inoue T, Cronkite E P, Hirabayashi Y, Bullis J E, Jr, Mitsui H, Umemura T. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Leukemia 1997; 11(Suppl 3)123–127
   PubMedGoogle Scholar